Page 16 - Read Online
P. 16

Tong et al. Hepatoma Res 2019;5:36  I  http://dx.doi.org/10.20517/2394-5079.2019.005                                            Page 11 of 13







































               Figure 3. Recurrence-free survival in hepatocellular carcinoma patients with slow vs. fast tumor growth rate by treatment category. TGR:
               tumor growth rate; OLT: orthotopic liver transplantation; RFA: radiofrequency ablation; TACE: transarterial chemoembolization

               for diagnosis of early HCC. Future studies using TGR along with other imaging criteria will assist in this
               endeavor.


               There are limitations to our study. This was a retrospective analysis of HCC patients from a single community
               specialty clinic. However all HCC treatments were performed at a university center where multi-disciplinary
               subspecialities were active in the care of these patietns. This scenario is much more representative of the real
               world setting since issues of long-term follow-up, financial constraints, and day to day care all came into play.
               Also, patients who did not have a second imaging study prior to HCC treatments were excluded from our
               analysis which may have biased patient selection. We did not compare the clinical outcome between patients
               who did or did not have a second imaging study, which may have clarified this issue. Also, we excluded
               patients with diffuse tumors since the diameter of the tumor could not be determined. However, these
               patients are usually not eligible for surgical or interventional radiologic treatment and have much shorter
               life expectancies. Further, only HCC patients with HBV or HCV were evaluated in this report. As such,
               additional studies should include other disease entities such as alcohol-related and nonalcoholic fatty liver
               disease-related HCC cases.


               In summary, our findings suggest that TGR is influenced by AFP, platelet counts, and albumin levels. TGR
               significantly influenced recurrence-free survival and response to surgical and locoregional treatments and
               may be another potential imaging biomarker to predict clinical outcomes in patients with HCC.


               DECLARATIONS
               Acknowledgments
               Jeffery Gornbein, Ph.D., assisted in the statistical analysis of the data; Lori Tong, RN, MSN, participated in
               the care of these patients; Alex Rosinski, B.S., M.A., assisted in the collection of data in this study.
   11   12   13   14   15   16   17   18   19   20   21